EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Circulating tumor HPV DNA, antibodies to HPV16 early proteins, and oral HPV16 DNA as biomarkers for HPV-related oropharyngeal cancer screening

Kristina R Dahlstrom iD, Andrew T Day iD, Victor M Alvarez, Samantha R Chirinos, Giselle Santillana, Ming Guo iD, Karen S Anderson iD, Erich M Sturgis iD

Cancer Biomarkers · 2025

DOI: 10.1177/18758592241313323 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Biomarkers, 2025. Verfasst von Kristina R Dahlstrom und 7 weiteren Autor:innen. Beteiligte Einrichtung: Section of Epidemiology & Population Sciences - Department of Medicine, Baylor College of Medicine, Houston, Texas, USA. Hauptthemen laut MEDLINE: Oropharyngeal Neoplasms, Human papillomavirus 16, Papillomavirus Infections, Biomarkers, Tumor. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, National Cancer Institute, Cancer Prevention and Research Institute of Texas.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Oropharyngeal cancer rates continue to rise with no effective screening method. Persistent oral oncogenic human papillomavirus (HPV), antibodies to HPV16 early (E) oncoproteins, and circulating tumor HPV DNA (ctHPVDNA) are biomarkers that show promise for use in HPV-related cancer screening.

Objective

To assess the prevalence of biomarkers for HPV-related cancer and their agreement in middle-aged men.

Methods

Men aged 50–64 years from the general population provided oral rinse and blood samples as well as information about demographics, tobacco/alcohol exposure, sexual behavior, and HPV-related disease history. Oral rinse was tested for HPV16 DNA and plasma was tested for HPV16 E antibodies and ctHPVDNA using a droplet digital PCR (ddPCR)-based assay that measures circulating tumor tissue modified viral (TTMV)-HPV DNA (NavDx, Naveris, Inc.). We calculated frequency distributions of variables of interest and agreement between the biomarkers.

Results

We enrolled 1045 subjects between April 2017 and April 2024. The 954 subjects with results for all three biomarkers were included in the analysis. The prevalence was 4.9% for oral HPV16 DNA, 0.7% for HPV16 E antibodies, and 0.5% for TTMV-HPV DNA.

Conclusions

The low prevalence of all three biomarkers shows their potential to identify high-risk individuals eligible for further clinical HPV-related cancer screening.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Oropharyngeal NeoplasmsHuman papillomavirus 16Papillomavirus InfectionsBiomarkers, TumorDNA, ViralAntibodies, ViralCirculating Tumor DNAOncogene Proteins, ViralHumansMaleMiddle AgedEarly Detection of Cancer

Stichwörter der Autor:innen

Cancer screeningHPV16 antibodiesbiomarkercirculating tumor tissue modified HPV DNAhead and neck neoplasmshuman papillomavirusoropharyngeal cancer

Substanzen

Biomarkers, TumorDNA, ViralAntibodies, ViralCirculating Tumor DNAOncogene Proteins, Viral

Autor:innen und Institutionen

  • Section of Epidemiology & Population Sciences - Department of Medicine, Baylor College of Medicine, Houston, Texas, USA.
  • Department of Otolaryngology-Head and Neck Surgery, The University of Texas Southwestern Medical Center, Dallas, Texas, USA.
  • Department of Otolaryngology-Head and Neck Surgery, Baylor College of Medicine, Houston, Texas, USA.
  • Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Biodesign Institute, Arizona State University, Tempe, Arizona, USA.

ORCID-Profile: Kristina R Dahlstrom, Andrew T Day, Ming Guo, Karen S Anderson, Erich M Sturgis

Förderung

  • NCI NIH HHS
  • National Cancer Institute
  • Cancer Prevention and Research Institute of Texas
  • Brown Foundation
  • Christopher and Susan Damico
  • Stiefel Oropharyngeal Research Fund
  • Lyda Hill Foundation

Zitieren

APA

Dahlstrom, K. R., Day, A. T., Alvarez, V. M., Chirinos, S. R., Santillana, G., Guo, M., Anderson, K. S., & Sturgis, E. M. (2025). Circulating tumor HPV DNA, antibodies to HPV16 early proteins, and oral HPV16 DNA as biomarkers for HPV-related oropharyngeal cancer screening. Cancer Biomarkers. https://doi.org/10.1177/18758592241313323

Vancouver

Dahlstrom KR, Day AT, Alvarez VM, Chirinos SR, Santillana G, Guo M, et al. Circulating tumor HPV DNA, antibodies to HPV16 early proteins, and oral HPV16 DNA as biomarkers for HPV-related oropharyngeal cancer screening. Cancer Biomarkers. 2025. doi:10.1177/18758592241313323

BibTeX
@article{Dahlstrom2025,
  author = {Dahlstrom, Kristina R and Day, Andrew T and Alvarez, Victor M and Chirinos, Samantha R and Santillana, Giselle and Guo, Ming and Anderson, Karen S and Sturgis, Erich M},
  title = {Circulating tumor HPV DNA, antibodies to HPV16 early proteins, and oral HPV16 DNA as biomarkers for HPV-related oropharyngeal cancer screening},
  journal = {Cancer Biomarkers},
  year = {2025},
  doi = {10.1177/18758592241313323}
}
Kostenlos starten →